Erratum: Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy

Correction to: Leukemia (2015) 29, 647–659; doi:10.1038/leu.2014.233; published online 29 August 2014

Following the publication of this article, the authors noted that there were errors in Figure 4a and c. The correct figure appears below:

Figure 4

Functional characterization of HLA class I AML-LiTAPs. (a) IFN-γ ELISPOT assay of AML patient PBMCs after stimulation with two different A*03-restricted AML LiTAP pools (P^I₁ and P^I₂). PHA served as a positive control, and stimulation with HIVGAG_18–26 A*03 peptide as a negative control. For P^I₁ and P^I₂ a significant IFN-γ production was observed. (b) Intracellular staining for IFN-γ and TNF-α of P^I₁- and P^I₂-stimulated AML patient PBMCs (same as in (a)). Phorbol myristate acetate (PMA)/ionomycin served as a positive control, and HIV GAG_18–26 A*03 peptide as a negative control. (c) Cross-checking IFN-γ ELISPOT assay of healthy donor PBMCs after stimulation with A*03-restricted AML LiTAP pools P^I₁ and P^I₂ revealed no significant IFN-γ production.